KCI Expands Offering of Next Generation Negative Pressure Wound Therapy Dressing
Jul. 11, 2018
SAN ANTONIO--(BUSINESS WIRE)--Jul 11, 2018--KCI, an Acelity Company, today announced the launch of the V.A.C. VERAFLO CLEANSE CHOICE™ Large Dressing designed for use with V.A.C. VERAFLO™ Therapy to cleanse larger wounds with thick, fibrous exudate and infectious material such as slough, and may be used on patients when surgical debridement must be delayed or is not possible or appropriate. With a unique, three-layer foam design with an array of holes, V.A.C. VERAFLO CLEANSE CHOICE™ Dressing allows for selective wound cleansing beyond traditional negative pressure wound therapy (NPWT) dressings, and provides flexibility in treating wounds of various depths.
“As an industry leader, we understand that wound care is incredibly complex and clinicians need more options – the combination of our core V.A.C.® Therapy technology with these new dressings shows remarkable potential for upending the traditional wound care approach, as illustrated by a growing body of clinical data,” said R. Andrew Eckert, President and CEO of Acelity. “Since launching V.A.C. VERAFLO CLEANSE CHOICE™ Dressing last year, we have seen tremendous response from clinicians with rapid adoption of the platform. Innovating for patients and customers is a driving force for our company, and we continue striving to revolutionize wound healing.”
V.A.C. VERAFLO™ Therapy consists of NPWT coupled with automated, controlled delivery to and removal of topical wound treatment solutions from the wound bed. It is unique in that it uses dressings, like CLEANSE CHOICE™, specifically designed for instillation therapy with NPWT that are less hydrophobic than the current V.A.C.® Therapy Dressings, to provide improved fluid distribution and removal from the wound bed.
“Not all wounds are the same – so it is imperative to have specialized wound care solutions to best manage and treat distinct wounds. The V.A.C. VERAFLO CLEANSE CHOICE™ Dressing allows for targeted wound cleansing, and has significantly changed the treatment pathway for many of my patients, particularly those with severe wounds who might not be candidates for surgical debridement, or who have wounds in hard-to-treat areas,” said Luis Fernandez, M.D., Christus Trinity Mother Frances Health System for Trauma, Tyler, TX. “Within my practice, I have seen how the therapy can have enormous implications for lowering the total cost of care for patients, clinicians and healthcare systems overall, by potentially reducing the number of operating room visits, decreasing the length of hospital stays, and helping to facilitate faster wound closure time.”
Clinical evidence continues to demonstrate V.A.C. VERAFLO™ CLEANSE CHOICE™ Dressing’s clinical benefits. In a retrospective analysis on 21 patients with large complex wounds using V.A.C. VERAFLO™ CLEANSE CHOICE™ Dressing, after three days, the majority of the fibrinous material and slough present in the wound bed was removed during therapy, with the following results: 1More than 85 percent of wounds had less than or equal to 10 percent surface area with black non-viable tissue remaining after an average of one to three applications (three to nine days of therapy). More than 57 percent of wounds had less than or equal to 10 percent surface area with yellow fibrinous slough remaining after an average of one to three applications (three to nine days of therapy). More than 95 percent of wounds displayed rapid granulation tissue formation under the portion of the foam directly in contact with the wound bed.
About V.A.C. VERAFLO CLEANSE CHOICE™ Dressing
V.A.C. VERAFLO CLEANSE CHOICE™ Dressing is used in conjunction with V.A.C. VERAFLO™ Therapy. Together they work quickly to cleanse contaminated wounds, by helping to soften, solubilize, and remove viscous exudate, wet slough, fibrin, and other infectious materials. 1 The unique, three-layer design can be used for wounds with complex geometries, including explored tunnels or undermining where the distal aspect is not visible. The contact layer with a pattern of 1 cm holes provides mechanical movement at the wound surface, in combination with cyclic delivery and dwell of topical solutions. The two cover layers without holes are designed to help capture large wound exudate before they enter the tubing, and they also provide application options for wounds with varying depths. For more information, visit www.VERAFLO.com.
About KCI, an Acelity Company
KCI, an Acelity Company, the most trusted brand in advanced wound care, is committed to developing innovative healing solutions for customers and patients across the care continuum. Our unsurpassed product portfolio is available in more than 90 countries and delivers value through solutions that speed healing and lead the industry in quality, safety and customer experience. Committed to advancing the science of healing, KCI sets the standard for leading advanced wound therapy innovation. Headquartered in San Antonio, Texas, KCI employs nearly 5,000 people around the world.
1 Teot L, Boissiere F, Fluieraru S. Novel foam dressing using negative pressure wound therapy with instillation to remove thick exudate. Int Wound J 2017;14:842-848.
View source version on businesswire.com:https://www.businesswire.com/news/home/20180711005476/en/
Kathryn Skeen, +1-210-882-2067
Jathan Tucker, +1-210-255-6816
KEYWORD: UNITED STATES NORTH AMERICA TEXAS
INDUSTRY KEYWORD: SURGERY HEALTH HOSPITALS MEDICAL DEVICES MEDICAL SUPPLIES NURSING
Copyright Business Wire 2018.
PUB: 07/11/2018 09:30 AM/DISC: 07/11/2018 09:31 AM